More on Gilead Sciences (GILD): Q2 beats across the board on a 14% rise in total revenue. Product sales - the company's leading revenue generator - rose 14% in the latest period. Sales of antiviral products, its dominant revenue stream, also increased 14% as HIV drugs Atripla and Truvada both saw sales increases of 10%. Royalty revenue decreased however, down 14% for the quarter. Shares +3% AH.